Corticosteroids for the treatment of Kawasaki disease in children
Referencias
Additional references
Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatrics International 2005;47(2):232‐4.
Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD004175.pub2]
Brogan P, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Archives of Disease in Childhood 2002;86(4):286‐90.
Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. Journal of the American College of Cardiology 1996;28(1):253‐7.
Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta‐analysis. Heart 2013;99(2):76‐82.
Daniels LB, Gordon JB, Burns JC. Kawasaki disease: late cardiovascular sequelae. Current Opinion in Cardiology 2012;27(6):572‐7.
Davies S, Gold‐von Simson G. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy?. Pediatric Cardiology 2013;34(7):1756.
Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Archives of Disease in Childhood 2013;99(1):74‐83.
Gardner‐Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch‐Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360(9341):1197‐202.
Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002;324(7351):1424‐5.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re‐treatment for immune globulin‐resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatrics International 2001;43(3):211‐7.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, et al. Long‐term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatrics International 2012;54(1):99‐103.
Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States; 1997 and 2000. Pediatrics 2003;112(3 Pt 1):495‐501.
Jones KS, Baumer JH, Gupta A, Dua JS. Steroid hormone treatment for Kawasaki disease in children. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD003284.pub2]
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63(2):175‐9.
Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long‐term consequences of Kawasaki disease. A 10‐ to 21‐year follow‐up study of 594 patients. Circulation 1996;94(6):1379‐85.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16(3):178‐222.
Kobayashi T, Inoue Y, Morikawa A. Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Japanese Journal of Clinical Medicine 2008;66(2):332‐7.
Levin M, Tizard EJ, Dillon MJ. Kawasaki disease: recent advances. Archives of Disease in Childhood 1991;66(12):1369‐72.
Levin M. Steroids for Kawasaki disease: The devil is in the detail. Heart 2013;99(2):69‐70.
Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009‐2010 nationwide survey. Journal of Epidemiology 2012;22(3):216‐21.
Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long‐term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110(17):2747‐71.
Oates‐Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004000]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Pediatric Heart Network Investigators. Evaluation of Kawasaki disease risk‐scoring systems for intravenous immunoglobulin resistance. The Journal of Pediatrics 2011;158(5):831‐5, e3.
Tatara K, Kusakawa S. Long‐term prognosis of giant coronary aneurysm in Kawasaki disease: An angiographic study. The Journal of Pediatrics 1987;111(5):705‐10.
Wood LE, Tulloh RM. Kawasaki disease in children. Heart 2009;95(10):787‐92.
